G alectin (Gal) family proteins are lectins that contain characteristic amino acid sequences and have an affinity for b-galactoside. Fifteen mammalian members of the Gal family of proteins have been sequenced and identified (1, 2) , and three Gal groups have been defined, as follows: those having one carbohydrate-recognition domain (CRD), Gal-1, -2, -5, -7, -10, -11, -13, -14, and -15; those having two CRDs, Gal-4, -6, -8, -9, and -12; and a chimera type, Gal-3 (1) . Gals can be found in the cytoplasm, nucleus, and extracellular environment (3), suggesting that they have diverse biological functions.
The results from accumulating studies indicate that Gals have important roles in the regulation of homeostasis and the effector function of immune cells (1, 4, 5) . Among Gal family proteins, the immunomodulatory roles of Gal-1 and Gal-3 have been studied extensively. In B cells, bone marrow-secreted Gal-1 anchors to integrins on pre-B cells to facilitate the localization of the pre-BCR into the synapse and to transduce a survival signal for pre-B cell development (6, 7) . The intracellular association of Gal-1 and B cell-specific coactivator (OCA-B) negatively regulates BCR signaling (8) . Our previous study demonstrated that Gal-1 is induced during the differentiation of mature B cells into Ig-secreting plasma cells, and this effect depends on the induction of B lymphocyte-induced maturation protein-1 (Blimp-1), the master regulator of plasma cell differentiation. We also showed that the induction of Gal-1 promotes the synthesis of Ig m-chain transcripts and the production of Ig (9) . Gal-3 is required for memory B cell fate in a Schistosoma-infected animal model (10) ; accordingly, Gal-3 prevents the differentiation of B1 cells into IgM-secreting plasma cells (11) . Gals recognize N-or O-linked glycans containing lactose, Galb1-4GlcNAc (type 2 N-acetyllactosamine [LacNAc]), or Galb1-3GlcNAc (type 1 LacNAc) (12, 13) . Gals have a higher affinity for LacNAc in poly-LacNAc repeats or in biantennary Nglycans (14) . N-glycan array studies of the glycan specificity of Gal-1 and Gal-3 indicate that unlike Gal-3, which preferentially recognizes internal or terminal poly-LacNAc chains, Gal-1 recognizes the terminal LacNAc in complex type N-glycans (15, 16) . Moreover, the modification of LacNAc by sialylation, fucosylation, or sulfation may determine the glycan specificity of Gals (12) . For example, Gal-1 binds to a3-sialylated and a2-fucosylated terminal LacNAc, but not to a6-sialylated or a3-fucosylated terminal LacNAc (14, 17) . Whether different Gals bind to selective types of modified LacNAc and whether the sum effect of those bindings contributes to the overall biological function of Gals are not well known.
In this work, we studied the role of Gal-1 and other Gals in the regulation of the differentiation of mature B cells into Ig-secreting plasma cells, and we analyzed how the binding of Gals to B cells influences the biological activities of the Gals. We show that Gal-1 and Gal-8 have redundant roles in promoting the formation of plasma cells and that Gal-1 and Gal-8 seem to selectively recognize ligands on mature B cells. These findings provide novel insights into how Gals collaboratively modulate immune responses.
Materials and Methods

Cell lines and reagents
Splenic B cells from 12-to 16-wk-old C57BL/6 mice (National Laboratory Animal Center, Taiwan) and from Lgals1 2/2 mice and littermate controls (provided by the Consortium for Functional Glycomics) were purified using B220 microbeads (Miltenyi Biotec). Purified splenic B cells (purity .95%) were cultured, as described (18) , and were stimulated with LPS (Sigma-Aldrich). The 293T, 3T3, and 293F cells were maintained, as described (9) . All chemicals were purchased from Sigma-Aldrich, unless otherwise indicated.
RNA isolation and quantitative RT-PCR
Total RNA isolation, cDNA synthesis, and subsequent quantitative RT-PCR (RT-QPCR) analysis of the cDNA in an ABI/Prism 7300 sequence detection system (Applied Biosystems) were conducted, as described (9), using the primers for SYBR Green incorporation. The primer sequences in this study are as follows: mouse Gal-1 (mGal-1), 59-TGCCAGACGGACATGAATTC-39 and 59-CATCCGCCGCCATGTAGT-39; mGal-2, 59-TAACCCTCGCTT-CGATGAATCC-39 and 59-AGCCCACCCATGCTCAAGTAGT-39; mGal-3, 59-TTGAAGCTGACCACTTCAAGGTT-39 and 59-AGGTTCTTCATCCG-ATGGTTGT-39; mGal-4, 59-ACCTGGAACTTCAGTCAATCA-39 and 59-TCCCTTGATTATGATGGTTCT-39; mGal-8, 59-GGGTGGTGGGTGGAA-CTG-39 and 59-GCCTTTGAGCCCCCAATATC-39; mGal-9, 59-TTTCAAT-GAGAATGCTGTTG-39 and 59-TTGAAGCAGTGACCTTCAC-39; XBP-1s, 59-TAGAAAATCAGCTTTTACGGGAGAAA-39 and 59-GGGCCTGCACCT-GCTGCGGACTCAG-39; a-2,3-sialyltransferase 1, 59-ATCTACCACCCAGC-CTTCA-39 and 59-TGTTCTCCCAGTAATGGTGC-39; a-2,6-sialyltransferase 1 (ST6Gal1), 59-CCTTCAACACCACTGAATGG-39 and 59-TAAACCTCAG-GACCGCATC-39; b1,6 N-acetylglucosaminyltransferase-1 (C2GnT), 59-TG-GAGCCCCTTACTAAAGAAGA-39 and 59-GCGGCTAAAAAGGATTCCT-39; Mgat5, 59-GTCTCTGGCGGAGAAACAAA-39 and 59-TGCTGTCTCC-GCAATCTTG-39. The primer information for mL32, Blimp-1, ms, and mm was described previously (9) .
Immunoblot analysis
The procedures for performing the immunoblot analysis were similar to those described previously (9) . The primary Abs used in this study are as follows: goat anti-Gal-1 Ab (1:500 dilution; Santa Cruz Biotechnology), goat anti-Gal-3 Ab (1:1000 dilution; R&D Systems), goat anti-Gal-8 Ab (1:500 dilution; Santa Cruz Biotechnology), mouse anti-FLAG Ab (1:1000 dilution; Sigma-Aldrich), and mouse anti-actin Ab (1:5000 dilution; Sigma-Aldrich). Secondary Abs are rabbit anti-goat IgG-HRP Ab (1:5000 dilution; Sigma-Aldrich) and rabbit anti-mouse IgG-HRP Ab (1:2500 dilution; Sigma-Aldrich).
Plasmids
Various eukaryotic expression vectors encoding Gal-1 were described previously (9) . Full-length mGal-3 and mGal-8 were amplified by RT-PCR from cDNA isolated from primary splenic B cells. The amplified product was cloned into a pCMV2-FLAG vector (Sigma-Aldrich) at BamHI/NotI sites to add a FLAG tag at the N terminus of Gal-3 and Gal-8. The FLAGtagged Gal-3 or Gal-8 fragments were then blunt-end digested and subcloned into a retroviral vector, pGC-YFP (19) . The protocol for generating short hairpin RNA (shRNA) for mGal-8 or the negative control in a lentiviral vector was essentially as described (20, 21) . The mGal-8 shRNA contains the sense targeting sequences 59-CATGTCCCTAAA-GATTCA-39 and 59-AGAAGAGGAGAGAAATAT-39, corresponding to nt 389-406 and 1027-1044, respectively, of the mGal-8 coding sequence (GenBank accession NM_018886; http://www.ncbi.nlm.nih.gov/nuccore/ NM_018886). These sequences were named Gal-8-389i and Gal-8-1027i, respectively. The detailed protocol for construction of these plasmids will be available upon request.
Retrovirus and lentivirus generation and transduction
The preparation of retroviral or lentiviral vectors and the transduction of the resulting viruses were performed, as described (22, 23) . Primary splenic B cells were transduced at a multiplicity of infection of 10 to 15, and transduced cells that expressed yellow fluorescent protein (YFP) or GFP were sorted 3 d later on a FACSAria (BD Biosciences).
Flow cytometry
B cells were harvested, washed in PBS once, and then suspended at a density of 10 6 cells/ml in PBS with 2% FBS. A total of 10 5 cells was used for each staining experiment. The following Abs were used: PE-conjugated antimouse CD138/syndecan-1 (BD Pharmingen; clone 281-2) and allophycocyanin-conjugated anti-mouse CD45R/B220 (BD Pharmingen; clone RA3-6B2). Biotin-conjugated Lycopersicon esculentum and Sambucus nigra lectins were purchased from EY Laboratories. Biotin-conjugated Maackia amurensis agglutinin (MAA) lectin was purchased from Vector Laboratories. Streptavidin-FITC-labeled secondary Ab was purchased from Serotec and used at a 1:500 dilution. Stained cells were analyzed using a FACSCanto (BD Biosciences), and the results were analyzed by FACSDiva software (BD Biosciences) or FCS Express v.3 software (DeNovo software). The protocol to detect the binding of Gal-Fc fusion proteins and FITC-labeled Gals was described previously (9) . For experiments that involved neuraminidase treatment, splenic B cells, adjusted to a density of 2 3 10 7 cells/ml with reaction buffer (50 mM sodium acetate [pH 5.5], 100 mM NaCl, 1 mM CaCl 2 , 100 mg/ml BSA), were treated with Salmonella typhimurium a2-3 neuraminidase (50 mU/ml; New England Biolabs), Clostridium perfringens a2-3,6 neuraminidase (50 mU/ml; New England Biolabs), or buffer alone at 37˚C for 15 min, followed by PBS washes and incubation with Gal-1-FITC or Gal-8-FITC. B cell proliferation determined by staining with CFSE (SigmaAldrich) was performed, as previously reported (9) .
ELISA and Multiplex bead array assays
Cell supernatants were harvested, and an ELISA was used to determine the amount of IgM or Gal-1, as described (9) . The amount of Gal-8 was determined using a Gal-8 ELISA kit (USCNLIFE). The amounts of IL-6 and IL-10 were determined by the MILLIPLEX mouse cytokine/chemokine kit (Millipore), as described previously (24) .
Production of Gal-Fc fusion proteins and bacterially expressed recombinant Gal proteins
Gal-1-Fc and Gal-8-Fc fusion proteins were produced in a Free-Style 293 expression system (Invitrogen), as described (9) . Recombinant Gal (rGal)-1 and Gal-8 were produced in a bacterial expression system, following reported methods (25) . Briefly, full-length human Gal-1 or murine Gal-8 cDNA was ligated to a pET-15b expression vector (Invitrogen), the resultant vector was transformed into Escherichia coli BL21 (DE3; Novagen), and expression was induced by incubation with 1 mM isopropyl b-Dthiogalactoside for 4 h at 37˚C. Bacteria were then lysed with B-PER extraction buffer (Pierce) with 0.1 M PMSF and 8 mM DTT. rGal-1 and rGal-8 were purified by lactosyl-Sepharose affinity chromatography and eluted with 0.1 M b-lactose. The 28-kDa dimeric Gal-1 was further isolated by a Superdex 75 gel filtration column (GE Healthcare). The expression of rGal-1 and rGal-8 was examined by 12% SDS-PAGE, followed by Coomassie blue staining. Endotoxin in bacterially expressed Gal-1 and Gal-8 was removed by Endo Trap Endotoxin Removal System (Lonza), and the endotoxin-free Gal-1 and Gal-8 were confirmed with the Limulus amebocyte lysate test using a kit from Lonza. rGal-1 and rGal-8 were then labeled with FITC using a Lightning-Link R-Fluorescein conjugation kit (Innova Biosciences).
Synthesis of LacNAc analogs
The procedures for synthesis of sulfated LacNAcs were mainly described in a publication (Z. Tu, H.-W. Hsieh, C.-M. Tsai, S.-G. Wang, K.-J. Wu, K.-I. Lin, and C.-H. Lin, submitted for publication), in which the efficient synthesis of fully protected Galb1-3/4GlcNAc disaccharides was carried out. Subsequent deprotection and sulfation steps resulted in eight non-or monosulfated saccharide products. All the products were carefully characterized by 1 H and 13 C nuclear magnetic resonance, optical rotation, and mass spectrometric analyses. The detailed protocol will be available upon request.
Statistical analysis
A two-sided Student t test was used for all statistical testing; p values ,0.05 were considered statistically significant.
Results
Gals are expressed differentially during plasma cell differentiation
Because Gal-1 is induced during the differentiation of mouse and human plasma cells, and because it can promote Ig production in vitro (9), we first sought to determine whether other Gals were involved in this process. Stimulation of purified splenic B cells with LPS mimics T cell-independent plasma cell differentiation and is characterized by IgM production and surface expression of B220 low CD138 + . Among the Gal family genes examined, Gal-1 mRNA increased after stimulation of splenic B cells with LPS (Fig. 1A) . The time course for the increase in Gal-1 mRNA expression paralleled the increase in Blimp-1 mRNA expression, in agreement with our previous work (9) . Levels of Gal-2, Gal-4, and Gal-9 were not detectable in LPS-stimulated B cells (Fig. 1A) . Gal-3 mRNA expression was low at day 0 and decreased further during differentiation (Fig. 1A) . Gal-8 mRNA expression was high on day 0 and decreased significantly after LPS stimulation (Fig. 1A) .
In a parallel study, flow cytometry was used to isolate day 0 B cells, B220 high CD138
2 undifferentiated B cells, and B220 low CD138 + plasma cells from LPS-stimulated splenic B cell cultures. RT-QPCR and immunoblot analysis were conducted with the isolated cell populations. Levels of Blimp-1 mRNA were used to confirm the identities of the sorted cell populations (Fig. 1B) . Gal-1 mRNA (Fig. 1B) and protein ( Fig. 1C ) increased during differentiation, with the highest levels found in plasma cells. Gal-3 expression was reduced in plasma cells (Fig. 1B, 1C ). Gal-8 mRNA decreased during differentiation and was lowest in plasma cells (Fig. 1B) , but Gal-8 protein increased during differentiation (Fig. 1C ). The accumulation of secreted Gal-1 as well as Gal-8 proteins in differentiated plasma cells was confirmed by ELISAs (Fig. 1D ).
Gal-1 and Gal-8, but not Gal-3, promote plasma cell formation
Because the expression of Gal-1, Gal-3, and Gal-8 was dynamically changed during the differentiation of plasma cells from B cells, we wondered whether Gal-3 and Gal-8, like Gal-1 (9), influence the formation of plasma cells. Primary B cells were transduced with bicistronic retroviral vectors encoding YFP and FLAG-tagged Gal-1, Gal-3, or Gal-8. Gal expression was confirmed by immunoblot analysis using an Ab against FLAG (Fig. 2A) . Ectopic expression of either Gal-1 or Gal-8 in LPS-stimulated mouse splenic B cells resulted in an increase in B220 low CD138
+ plasma cells, as compared with cells that expressed only YFP (Fig. 2B) . Ectopic expression of Gal-3 did not increase the proportion of B220 low CD138
+ plasma cells (Fig. 2B) . The YFP + cells were also sorted and analyzed for levels of secreted IgM in culture. Ectopic expression of Gal-1 or Gal-8 significantly increased IgM secretion (Fig. 2C) . Gal-3, however, did not alter IgM production (Fig. 2C) . This effect of Gal-1 and Gal-8 could be due to an extracellular effect, as ectopically expressed Gal-1 and Gal-8 were both produced in culture media (Fig. 2D) . Furthermore, sorted cells were used to examine the expression of plasma cell-associated genes in cells that overexpressed Gal-8, relative to Gal-1 or YFP alone. Ectopic expression of Gal-8 significantly increased the mRNA levels of Blimp-1 and the spliced form of XBP-1 (XBP-1s), genes that are crucial for plasma cell differentiation and Ab secretion (26) , respectively, in comparison with cells that overexpressed Gal-1 or YFP (Fig. 2E) . We also examined the ratio of the secreted form (ms) to the membrane form (mm) of m-chain mRNA and found that, like Gal-1, Gal-8 was able to enhance the splicing of the m-chain mRNA (Fig. 2F) . These data reveal a new role for Gal-8 and its underlying molecular effects in promoting plasma cell formation.
Gal-1 and Gal-8 bind more effectively to mature B cells than to plasma cells Because both Gal-1 and Gal-8 promoted the formation of plasma cells, we sought to determine their binding profile during differentiation. Bacterially expressed rGal-1 and rGal-8 were purified, monitored (Fig. 3A) , and labeled with FITC. Gal-1-FITC and Gal-8-FITC bound to mature B cells, and binding was dependent on galactoside recognition, because coincubation with lactose, but not sucrose, blocked the binding of Gal-1-FITC and Gal-8-FITC FIGURE 1. Gal expression during plasma cell differentiation. A, RT-QPCR was used to determine mRNA levels for the indicated Gals relative to the level of the internal control, mL32, at days 0, 1, and 3 after LPS (5 mg/ml) stimulation of splenic B cells. B, RT-QPCR was used to determine mRNA levels of the indicated Gals relative to levels of the internal control, mL32, in cell populations that were sorted on the basis of staining for B220 and CD138. A representative flow cytometry dot plot is shown. C, Immunoblot analysis was used to examine protein expression of Gal-1, Gal-3, and Gal-8 in sorted cell populations. Actin was used as the loading control. D, ELISA was used to determine levels of secreted mGal-1 and mGal-8 in day 3 culture supernatants from control (2) and LPS-stimulated (+) splenic B cells used in the assay presented in A. The results shown in A, B, and D are represented as the mean 6 SD (n = 3). *p , 0.05, **p , 0.01, ***p , 0.005. to the cells (Fig. 3B) . We then examined the ability of Gal-1 to compete with Gal-8 for binding to mature B cells, and vice versa. Splenic B cells were incubated with lactose to remove the bound Gal and incubated with Gal-1-FITC along with 0 (mock), 1, 3, or 10 mM unlabeled Gal-8, followed by flow cytometric analysis of Gal-1-FITC binding. The binding of Gal-1-FITC to B cells was blocked by Gal-8 in a dose-dependent manner (Fig. 3C, left  panel) . In the reciprocal experiment, Gal-1 did not alter the binding of Gal-8-FITC to mature B cells (Fig. 3C, right panel) . These data suggest that the available glycan ligands for Gal-1 and Gal-8 on mature B cells may, at least in part, differ in terms of their sequences, quantity, or spatial accessibility. As an alternative approach to examine Gal binding, we generated Gal-1-Fc and Gal-8-Fc fusion proteins and validated the expression (Fig. 3A) , and then analyzed their binding to specific cell populations by flow cytometry. After stimulation of splenic B cells with LPS, Gal-8-Fc bound less effectively to B220 low CD138 + plasma cells than to B220 high CD138 2 B cells (Fig. 3D ). This was also true for Gal-1-Fc binding (Fig. 3D ). Similar phenomena were observed when FITC-labeled Gal-1 or Gal-8 was used for staining (Fig. 4C) .
To further understand why the binding of Gal-1 and Gal-8 decreased during differentiation of B cells into plasma cells, we examined the expression of glycosyltransferase genes in sorted B220 high CD138 2 B cells and B220 low CD138 + plasma cells. RT-QPCR showed that mRNA expression of a-2,3-sialyltransferase 1 (ST3Gal1), which transfers sialic acid with an a-2,3 linkage to Oglycans (27) , was similar in the two cell populations (Fig. 4A) , but mRNA expression of ST6Gal1, which catalyzes the formation of a-2,6-sialylated N-glycans (28, 29) , was much greater in plasma cells than in B cells (Fig. 4A) . mRNA expression of C2GnT, which is involved in the formation of GlcNAcb1-6 (Galb1-3) structures in the core 2 O-glycan branch (30) , and mRNA expression of Mgat5, which catalyzes the b1-6 branching of N-GlcNAc on N-glycan (31), were lower in plasma cells than in B cells (Fig. 4A) . Because the expression of C2GnT and Mgat5 is positively correlated with the elongation of LacNAc (32, 33) , and the a-6 sialylated LacNAc structure prevents Gal-1 binding (29), our glycosyltransferase expression data are consistent with the finding that the binding of Gal-1 and Gal-8 decreases during the differentiation of plasma cells. In agreement with these findings, we found that the binding of L. esculentum, a tomato lectin that has a high affinity for GlcNAc and poly-LacNAc (34), was lower on B220 low CD138 + plasma cells than on B220 high CD138
2 B cells (Fig. 4B ). In addition, the binding of MAA lectin, which recognizes the a2-3 sialic acid linkages (35) , was undistinguishable between B220 low CD138 + plasma cells and B220 high CD138
2 B cells (Fig. 4B) . However, the binding of S.
nigra, a lectin that preferentially recognizes a2-6 sialic acid linkages (35), was only slightly increased in B220 low CD138 + plasma cells (Fig. 4B) , which could be because ST6Gal1 preferentially used N-glycans as its substrates, producing only a partial FIGURE 2. Gal-1 and Gal-8 promoted the differentiation of plasma cells. A, Immunoblot analysis was used to examine the expression of FLAG-tagged Gal-1, Gal-3, and Gal-8 using a retroviral vector. Actin was used as the internal loading control. The molecular mass markers (in kDa) are shown on the left of the blot. B, Ectopic expression of Gal-1 and Gal-8, but not Gal-3, promoted the generation of B220 low CD138 + plasma cells from purified splenic B cells stimulated with LPS (0.5 mg/ml). Cells were harvested 3 d after transduction, stained for B220 and CD138, and analyzed by flow cytometry with gates set on YFP + cells. C, Ectopic expression of Gal-1 and Gal-8 promoted the production of IgM from splenic B cells stimulated with LPS and transduced with the indicated retroviral vectors. YFP + cells were sorted on day 2, and the sorted YFP + cells were cultured for an additional day before supernatants were collected for determination of IgM levels by ELISA. D, ELISA was used to show the secretion of retrovirally expressed Gal-1 and Gal-8 from supernatants collected in C. E and F, Relative mRNA levels of Blimp-1 and XBP-1s (E) and the ratio of ms mRNA versus mm mRNA (F) in sorted YFP + cells, as in C. Results are shown as the mean 6 SD (n = 3). *p , 0.05, **p , 0.01, ***p , 0.005. repertoire for S. nigra binding. Interestingly, it appears that the a2-6 sialic acid linkages on B220 low CD138
+ plasma cells prevented the binding of Gal-1 and Gal-8, because treating differentiating splenic B cells with a2-3,6 neuraminidase, which removes sialic acids from oligosaccharides that are either a2-3 or a2-6 linked (data not shown), but not with a2-3 neuraminidase, restored the binding of Gal-1-FITC and Gal-8-FITC to B220 low CD138 + plasma cells (Fig. 4C ). All together, these data show that Gal-1 and Gal-8 share a similar binding profile to B cells and plasma cells, and that there is an association between Gal-1 and Gal-8 binding and glycosyltransferase expression.
Gal-1 and Gal-8 have selective ligands
We next wished to determine whether Gal-1 and Gal-8 recognize different glycans. A comparison of glycans that bind Gal-1 and Gal-8 based on data from the Web site of the Consortium for Functional Glycomics revealed that nearly half of the Gal-1-binding ligands also bind to Gal-8 (Supplemental Table 1 ). Interestingly, compounds that have sulfomodification at the C3 of galactose of type 2 LacNAc appear to bind to Gal-1 better than to Gal-8 (Supplemental Table 1 ). This observation prompted a study into the effects of various sulfated LacNAc derivatives on the binding of Gal-1 and Gal-8 to B cells. We used a panel of synthetic LacNAc analogs that contain sulfomodification at galactose or GlcNAc of type 1 or type 2 LacNAc (Fig. 5A) . For instance, a compound that has a monosulfate modification at the C3 of galactose (39) of type 2 LacNAc was named 39SII; a compound that has a monosulfate modification at the C6 of GlcNAc (6) of type 1 LacNAc was named 6SI.
Several type 2 LacNAc analogs, including II, 6SII, and 39SII, blocked the binding of Gal-1 to purified splenic B cells in a concentration-dependent manner (Fig. 5B, left panel) ; among these analogs, 39SII was most effective. In contrast, none of the type 2 LacNAc analogs altered the binding of Gal-8 to B cells (Fig. 5C,   left panel) . Type 1 LacNAc analogs, including I, 6SI, and 69SI, were less effective than type 2 LacNAc analogs at blocking the binding of Gal-1 to B cells (Fig. 5B, right panel) . Interestingly, some type 1 LacNAc analogs, including I, 6SI, and 39SI, can partially block the binding of Gal-8 to B cells (Fig. 5C, right  panel) ; 6SI was most effective at blocking Gal-8 binding. The quantitative data also revealed that 6SI was most effective at inhibiting Gal-8 binding (Supplemental Fig. 1 ).
Gal-1 promotes the stimulus-mediated induction of Ig (9) . We showed that B cells from Gal-1 knockout (Lgals1 2/2 ) mice differentiated normally in response to LPS stimulation, with B cell cultures from Lgals1 +/+ and Lgals1 2/2 mice having comparable frequencies of B220 low CD138 + plasma cells (Fig. 6A) . We suspected that Gal-8 might accumulate in B cells during differentiation, and that this might compensate for the absence of Gal-1 in (Fig. 6A) .
Treatment with I did not change, and treatment with 6SI only partly altered plasma cell formation in Lgals1 +/+ B cell cultures (Fig. 6A) . The 69SI produced no effect on plasma cell formation in Lgals1 2/2 and Lgals1 +/+ B cell cultures (Fig. 6A ), in agreement with its lack of effect on Gal-8 binding (Fig. 5C ). In agreement with these results, I and 6SI, but not 69SI, significantly reduced IgM production by LPS-stimulated Lgals1 2/2 B cells, when compared with the corresponding compound-treated, LPSstimulated Lgals1 +/+ B cells (Fig. 6B ). To further investigate whether depletion of Gal-8 combined with loss of Gal-1 prevents plasma cell differentiation, we generated shRNA specifically against mGal-8, mGal-8-389i, and mGal-8-1027i. Splenic B cells were transduced with the shRNA(s) expressing lentiviral vectors, and Gal-8 mRNA (Supplemental Fig. 2 ) and protein (Fig. 6C ) levels were analyzed. We found that Gal-8-389i and Gal-8-1027i decreased Gal-8 mRNA and protein expression (Fig. 6C, Supplemental Fig. 2 ). Control shRNA (Ctrli)-transduced and LPS-stimulated B cells from Lgals1 2/2 and Lgals1 +/+ mice produced similar amounts of IgM (Fig. 6D) . As expected, when compared with stimulated and transduced Lgals1 +/+ B cells, LPS-stimulated B cells from Lgals1 2/2 mice expressing Gal-8-389i or Gal-8-1027i produced less IgM (Fig.  6D) . These data indicate a redundancy in the effects of Gal-1 and Gal-8 on plasma cell formation.
We also examined the effects of both Gal-1 and Gal-8 that resulted from their extracellular functions. Interestingly, as compared with the exogenously added rGal-1, which induces the formation of Absecreting plasma cells (9) , exogenously added rGal-8 was even more potent for promoting the generation of Ab-secreting plasma cells (Fig. 7A, 7B) . Particularly, it is noteworthy that rGal-1 and rGal-8 had an additive effect in this setting (Fig. 7A, 7B ). This extracellular effect of Gal-1 and/or Gal-8 was further supported by the efficient inhibition of plasma cell formation and IgM production when cells were cotreated with 6SI, which blocked the binding of both rGal-1 and rGal-8, but not with 69SI (Fig. 7C, 7D ).
Discussion
Gals have been suspected of having redundant roles in the regulation of diverse biological processes because all Gals recognize galactose, with the exception of Gal-11, which lacks several key residues in the CRD for sugar binding (36) . In the current study, we used synthetic sulfated LacNAc analogs and shRNAs against Gal-8 to reveal a redundancy in the roles of Gal-1 and Gal-8 in the formation of plasma cells.
Our previous study revealed a glycan-dependent effect of Gal-1 on the promotion of plasma cell differentiation (9 (37) . Gals having long linker peptides, such as the long form of Gal-8 and Gal-9, are more susceptible to thrombin cleavage, whereas Gals having short linker peptides, such as the short form of Gal-8 and Gal-9, are resistant to thrombin cleavage (37) . The Gal-8 mRNA detected in our cultures www.jimmunol.org was primarily in the short form (data not shown); therefore, we propose that Gal-8 accumulates in plasma cells because the Gal-8 protein produced during plasma cell differentiation is relatively resistant to proteolysis. Gal-8 acts as an extracellular modulator to induce apoptosis in thymocytes (38) , and it acts as a matrix protein that promotes cell adhesion by clustering cell surface integrin receptors (39) . In the current study, we observed that ectopic expression of Gal-8 as well as treatment with rGal-8 in B cells promoted the generation of plasma cells. Furthermore, certain LacNAc derivatives had a stronger affinity for Gal-8 than did others, and shRNA against Gal-8 selectively diminished plasma cell production by Lgals1 2/2 B cells, indicating that both Gal-1 and Gal-8 are involved in plasma cell formation. Indeed, both Gals were able to activate splenic B cell proliferation (Supplemental Fig. 3A) , a crucial event prior to efficient plasma cell differentiation, and induce the production of IL-10 (Supplemental Fig. 3B ), a plasma cell differentiation factor. Although both Gals are redundant in plasma cell formation, we speculated that each Gal may stimulate at least partly distinct signaling pathways because we observed that Gal-8, but not Gal-1, was able to induce Blimp-1 mRNA, and that Gal-8, but not Gal-1, significantly induced the production of plasma cell proliferative factor, IL-6, in this setting (Supplemental Fig. 3B ). It will be important to further dissect the signaling pathways initiated by Gal-1 or Gal-8. Nevertheless, the redundancy of Gal-1 and Gal-8 seems to be unique to B cells because Gal-1 acts in T cells to modulate the balance between Th1, Th17, and Th2 immune responses. Indeed, Lgals1 2/2 mice show exaggerated Th1 and Th17 responses after Ag challenge in vivo (35) . Our study showed that Gal-8 competed with Gal-1 for binding to mature B cell surfaces, but Gal-1 did not compete with Gal-8 for binding. It is unclear how Gal-8 ligands on mature B cell surfaces overlap with Gal-1 ligands. The glycan ligands recognized by Gal-8 have been determined by a glycan microarray (40) . Gal-8 recognizes sulfated glycans, sialylated glycans, and poly-LacNAc structures. Notably, the N-terminal CRD of Gal-8 can bind to type 1 LacNAc, but the C-terminal CRD of Gal-8 has a higher binding affinity for poly-LacNAc structures (40) . The differential biological activities of the N-versus C-terminal CRD of Gal-8 have been shown (41) , including in killing E. coli strains (42), in activating platelets (43) , and in modulating neutrophil function (44); however, which CRD of Gal-8 is responsible for its positive role in plasma cell formation remains to be determined. In the current study, sulfomodified Gals or GlcNAc on type 1 or type 2 LacNAcs were used as competitors to elucidate the binding ligands for Gal-1 and Gal-8 on mature B cell surfaces. Gal-1 had a strong binding affinity for type 2 and sulfated type 2 (6SII and 39SII) LacNAcs, but less for type 1 LacNAcs. Gal-8 had a stronger binding affinity for the type 1 LacNAcs, 6SI and 39SI. B cells express b-1,3-galactosyltransferase (45, 46), which is involved in the synthesis of the b-1,3 linkage structure of the type 1 chain (47) . Whether the B cell surface expresses type 1 LacNAc or sulfated type 1 LacNAc remains to be examined. Nevertheless, our cell-based assays revealed ligands that may be preferentially recognized by Gal-1 and Gal-8. Further identification of the natural glycan ligands for Gal-1 and Gal-8 on B cells will be important to fully understand their mode of action in plasma cell differentiation.
Like Gal-1, Gal-8 had a stronger binding affinity for mature B cells than for plasma cells. One possible explanation for why Gal-1 and Gal-8 did not bind as strongly to plasma cells is related to a reduction in overall glycans and an increase in a2-6 sialic acid linkages in plasma cells. In fact, L. esculentum lectin showed decreased binding to plasma cells, suggesting that longer and more complex glycan structures might be expressed on activated mature B cells than on plasma cells. Our data also showed that Mgat5 and C2GnT mRNA levels were significantly decreased in plasma cells, which supports the idea that the expression of glycan structures for Gals binding was generally reduced. Furthermore, our observation that a2-3,6 neuraminidase, but not a2-3 neuraminidase, treatment restored the binding of Gal-1 and Gal-8 to plasma cells is also in agreement with the notion that a6-sialylated terminal LacNAc prevents Gal binding (14, 17) . A second explanation is that protein receptors for Gal-1 and Gal-8 might be also downregulated during plasma cell differentiation. In T cells, the protein receptors for Gal-1 include CD45, CD43, and CD7 (48) , and interactions between Gal-1 and those receptors are associated with the expression of C2GnT and Mgat5 (35) . Gal-8 interacts with CD44 on synovial fluid cells to regulate autoimmune inflammation in rheumatoid arthritis (49) . In addition, ligation of CD45 by Gal-8 leading to the proliferation of T cells via the activation of ZAP70 and ERK1/2 signaling pathways has also been shown (50) . The protein receptors present on the mature B cell surface for Gal-1 and Gal-8 are, however, still unknown.
In addition to Gal-1 and Gal-8, Gal-3 was expressed in B cells, but levels of Gal-3 declined upon differentiation. Gal-3 expression is induced by IL-4 or CD40L in B cells, and Gal-3 expression during B cell activation might lead to the differentiation of memory B cells, not plasma cells (51) . In agreement with those findings, we found that Gal-3 did not affect plasma cell generation or IgM production. We did, however, find that ectopic expression of Gal-3 in LPS-stimulated mouse splenic B cells promoted Ig gene class switching to IgG, particularly IgG2b (data not shown). Combining these results, we speculate that Gal-3 promotes germinal center reaction and memory B cell formation in vivo, but does not significantly promote plasma cell differentiation.
In summary, our study identified a new role for Gal-8, which is likely to function extracellularly, and a redundancy in the effects of Gal-1 and Gal-8 on plasma cell differentiation. We further demonstrated that a sulfated type 1 LacNAc can selectively interfere with the function of Gal-8 in B cells. This finding may be useful for designing a selective target for the modulation of B cell function.
